| Tumor | Author | Year | Method | No. of Patients | Title | Journal | Abstract Link |
| Bladder | Ademaj | 2023 | RT+HT | 21 | Radiotherapy combined with deep regional hyperthermia in elderly and frail patients with muscle-invasive bladder cancer: quality analysis of hyperthermia and impact on clinical results | Int J Hyperthermia |  |
| Bladder | Wen | 2021 | CT+HT | 43 | Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer | Int J Hyperthermia | |
| Bladder | Brummelhuis | 2021 | CRT+HT | 274 | Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer | Cancers | |
| Bladder | Merten | 2019 | RCT+HT | 369 | Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer |
The Oncologist | |
| Bladder | Datta | 2019 | CRT+HT | 16 | A Pilot Study of Radiotherapy and Local Hyperthermia in Elderly Patients With Muscle-Invasive Bladder Cancers Unfit for Definitive Surgery or Chemoradiotherapy | Front Oncol | |
| Bladder | Inman | 2014 | CT+HT | 15 | A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer | Int J Hyperthermia | |
| Bladder | Juang | 2014 | CT+HT | 14 | Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer | Int J Hyperthermia | |
| Bladder | Wittlinger | 2009 | RCT+HT | 45 | Quadrimodal treatment of high-risk T1 and T2 bladder cancer: Transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia | |
|
| Bladder | Van der Zee | 2000 | MMC+RT vs. RT+HT |
101 | Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumors: a prospective, randomized, multicentre trial. Dutch Deep Hyperthermia Group | Lancet | |
Benefits of Hyperthermia in Cancer Treatment*
Effects Tumor Cell
In the delicate micro-environment of a cancer cell, heat can lead to direct cell death, shrinking tumor size for easier surgical resection.
Low Toxicity
Very low to no toxicity is often reported when administering hyperthermia. There is no known toxicity build-up from multiple treatments.
Increase Blood Flow
Increased blood flow and perfusion at the tumor site promote oxygenation, increasing radiosensitivity.
Survival Benefit
A phase III clinical study shows an increased survival benefit when hyperthermia was added to traditional therapies.
Inhibits DNA Repair
Hyperthermia, in combination with Radiotherapy, will inhibit the DNA repair cycle of radiation-damaged cancer cells.
Heat Shock Proteins
Tumor cells express heat shock proteins when exposed to hyperthermic temperatures allowing tumor-specific antigens to reach the immune system.
